Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on EKSO BIONICS, with a price target of $6.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Swayampakula Ramakanth has given his Buy rating due to a combination of factors including a significant recovery in Ekso Bionics’ quarterly sales and improved gross margins. The company reported a strong sequential growth in revenue for the third quarter of 2025, which rebounded from a previous quarter that had underperformed due to specific order delays. This recovery suggests that the earlier issues were unique and not indicative of a broader trend.
Additionally, Ekso Bionics is exploring strategic transactions that could potentially enhance its business operations, although the outcome and timeline of these transactions remain uncertain. Financially, the company has shown resilience by exceeding consensus revenue estimates and reducing its net loss per share. The analyst’s valuation, which includes various financial models, supports a 12-month price target increase to $6, reflecting confidence in the company’s future performance despite existing risks such as commercial, clinical, and regulatory challenges.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EKSO in relation to earlier this year.